Page 58 - Read Online

Feun et al. Immunotherapy for hepatocellular carcinoma

19. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu Checkmate-040 dose escalation study. In: Proceedings of the 52th
WZ, Wang L, Tang ZY, Sun HC. High expression of macrophage Annual Meeting of the American Society of Clinical Oncology; 2016
colony-stimulating factor in peritumoral liver tissue is associated with June 4-8; Chicago. ASCO 2016. Abstract nr 4012.
poor survival after curative resection of hepatocellular carcinoma. J 33. El Ansary M, Mogawer S, Elhamind SA, Alwakil S, Aboelkasem
Clin Oncol 2008;26:2707-16. F, Sabaawy HE, Abdelhalim O. Immunotherapy by autologous
20. Yeung OW, Lo C, Ling C, Qi X, Geng W, Li CX, Ng KT, Forbes dendritic cell vaccine in patients with advanced HCC. J Cancer Res
SJ, Guan XY, Poon RT, Fan ST, Man K. Alternatively activated Clin Oncol 2013;139:39-48.
(M2) macrophages promote tumor growth and invasiveness in 34. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho
hepatocellular carcinoma. J Hepatol 2015;62:607-16. M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman
21. Barathan M, Gopal K, Mohamed R, Ellegard R, Saeidi A, T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K,
Vadivelu J, Ansari AW, Rothan HA, Ram MR, Zandi K, Chang Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang
LY, Vignesh R, Che KF, Kamarulzaman A, Velu V, Larsson M, TH, Kirn DH. Randomized dose-finding clinical trial of oncolytic
Kamarul T, Shankar EM. Chronic hepatitis C virus infection triggers immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med
spontaneous differential expression of biosignatures associated 2013;19:329-36.
with T cell exhaustion and apoptosis signaling in peripheral blood 35. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY,
mononucleocytes. Apoptosis 2015;20:466-80. Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ,
22. Li FJ, Zhang Y, Jin GX, Yao L, Wu EQ. Expression of LAG-3 is Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH. Use of
coincident with the impaired effector function of HBV-specific a targeted oncolytic poxvirus, JX-594, in patients with refractory
CD8(+) T cell in HCC patients. Immunol Lett 2013;150:116-22. primary or metastatic liver cancer: a phase I trial. Lancet Oncol
23. Cariani E, PilliM, Zerbini A, Rota C, Olivani A, Zanelli P, Zanetti 2008;9:533-42.
A, Trenti T, Ferrari C, Missale G. HLA and killer immunoglobulin- 36. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ,
like receptor gene as outcome predictors of hepatitis C virus-related Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns
hepatocellular carcinoma. Clin Can Res 2013;19:5465-73. J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS,
24. Guo Q, Lan P, Yu X, Han Q, Zhang J, Tian Z, Zhang C. Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH.
Immunotherapy for hepatoma using a dual-function vector with both Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic
immunostimulatory and Pim-3-silencing effects. Mol Cancer Ther poxvirus in humans. Nature 2011;477:99-102.
2014;13:1503-13. 37. Nakamoto N, Kaplan DE, Coleclough J, Li Y, Kaminski M, Shaked
25. Watanabe T, Bertoletti, A, Tanoto TA. PD-1/PD-L1 pathway and A, Olthoff K, Gostick E, Price DA, Freeman GJ, Wherry EJ, Chang
T-cell exhaustion in chronic hepatitis virus infection. J Viral Hepat KM. Functional restoration of HCV-specific CD8 T cells by PD1
2010;17:453-8. blockade is defined by PD1 expression and compartmentalization.
26. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Gastroenterology 2008;134:1927-37.
Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells 38. Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, Kaminski M,
during chronic viral infection. Nature 2006;439:682-7. Gostick E, Price DA, Freeman GJ, Wherry EJ, Chang KM. Synergistic
27. Yin XY, Lü MD, Liang LJ, Lai JM, Li DM, Kuang M. Systemic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by
chemo-immunotherapy for advanced-stage hepatocellular carcinoma. combined PD-1/CTLA-4 blockade. PLos Pathog 2009;5:e1000313.
World J Gastroenterol 2005;11:2526-9. 39. Liao J, Xiao J, Zhou Y, Liu Z, Wang C. Effect of transcatheter
28. Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano arterial chemoembolization on cellular immune function and
RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese regulatory T cells in patients with hepatocellular carcinoma. Mol
JL, Vauthey JN. Modified cisplatin/interferon α-2b/doxorubicin/5- Med Rep 2015;12:6065-71.
fluorouracil (PIAF) chemotherapy in patients with no hepatitis or 40. Guan H, Wang J, Yang M, Song Li, Tong X, Zou YH. Changes
cirrhosis is associated with improved response rate, resectability, and in immunological function after treatment with transarterial
survival of initially unresectablehepatocellular carcinoma. Cancer chemoembolization plus radiofrequency ablation in hepatocellular
2013;119:3334-42. carcinoma patients. Chin Med J (Engl) 2013;126:3651-5.
29. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo 41. Duffy AG, Makarova-Rusher OV, Pratt D, Kleiner DE, Fioravanti S,
FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Walker M, Carey S, Figg WD, Steinberg SM, Anderson V, Levy E,
Tang A, Johnson PJ. A randomized phase III study of doxorubicin Krishnasamy V, Wood BJ, Greten TF. Tremelimumab, a monoclonal
versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil antibody against CTLA-4, in combination with subtotal ablation
(PIAF) combination chemotherapy for unresectable hepatocellular (trans-catheter arterial chemoembolization [TACE], radiofrequency
carcinoma. J Natl Cancer Inst 2005;97:1532-8. ablation [RFA] or cryoablation) in patients with hepatocellular
30. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda carcinoma (HCC) and biliary tract carcinoma (BTC). J Clin Oncol
E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte 2016;34 suppl 4:abstr 270.
JJ, Pérez-Gracia JL, Melero I, Prieto J. A clinical trial of CTLA- 42. Wang Q, Yu T, Yuan Y, Zhuang H, Wang Z, Liu X, Feng
4 blockade with tremelimumab in patients with hepatocellular M. Sorafenib reduces hepatic infiltrated regulatory T cells in
carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8. hepatocellular carcinoma patients by suppressing TGF-beta signal. J
31. El-Koueiry AB, Melero I, Crocenzi TS, Welling TH. Phase I/II Surg Oncol 2013;107:422-7.
safety and antitumor activity of nivolumab in patients with advanced 43. Hipp M, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP,
hepatocellular carcinoma (HCC): CA209-040. In: Proceedings of the Weinschenk T, Singh-Jasuja H, Brossart P. Sorafenib, but not
51th Annual Meeting of the American Society of Clinical Oncology; sunitinib, affects function of dendritic cells and induction of primary
2015 May 30-June 2; Chicago. ASCO 2015. Abstract nr LBA 101. immune response. Blood 2008;111:5610-20.
32. El-Koueiry AB, Sangro B, Yau T, Crocenzi TS, Welling III TH, Yeo 44. Martin del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP,
W, Chopra A, Anderson J, dela Cruz C, Lang L, Neely J, Melero Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-
I. Phase 1/2 safety and antitumor activity of Nivolumab in patients Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD,
with advanced hepatocellular carcinoma: interim analysis of the McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A,
50 Hepatoma Research ¦ Volume 3 ¦ March 22, 2017